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Antibiotic susceptibility testing and breakpoint 
determination 
To the Editors: 
Re:  Phillips I .  Clin Microbiol Infect 1995; l(1): 65-6 
O n  behalf of the Susceptibility Testing Working Party 
of the British Society for Antimicrobial Chemotherapy, 
I would like to endorse the views of the President of 
ESCMID in his aim to move to comparable suscepti- 
bility testing within Europe. The initial move to 
develop a reference method is commendable as it avoids 
the imposition of a standard method. The options for 
a reference method will have to be carefully considered 
as different methodologies are more applicable for 
different situations. A reference method, in my 
opinion, will have to be a minimum inhibitory con- 
centration (MIC) determination as a disk-diffusion 
method, by necessity, is based on MICs. I note that 
Professor Phillips suggests a broth-dilution MIC deter- 
mination for a reference procedure. It is our experience 
that agar-dilution procedures are highly flexible and 
often give clearer endpoints and, hence, are more 
reproducible. Both methods are equally open to 
automation. It is possible for two equivalent reference 
methodologies to be investigated. 
It  is my view that, in the UK, there is a need for a 
change from the Stokes methods employed for disk 
testing, an opinion I know to be shared by others. At 
present, work ongoing in my department, involving 
colleagues in France, Belgium and Italy, and using 
different disk-diffusion methodologies, suggests that 
our results are very similar. We have more in common 
than differences among us. Now is the time for possible 
change. 
Richard Wise 
Chairman, BSAC Working Party 
London. UK 
Continuing medical education (CME) credits and 
multiple-choice questions 
To the Editors: 
Re:  Speller et al., Clin Microbiol Infect 1995; l(1): 54-9 
I have read with interest the paper on glycopeptide 
resistance in gram-positive bacteria and completed the 
multiple-choice questions (MCQ) . 
Medical practitioners living in remote areas away 
from centers of medical education may struggle to gain 
sufficient CME credits to maintain accreditation in 
their professional disciplines. Perhaps the M C Q  in your 
journal could be marked according to some arrange- 
ment with the institutions involved in the awarding of 
credits for CME? 
An example of how this can be done is seen in the 
monthly state-of-the-art clinical articles published in 
Clinical Infectious Diseases in the United States. This 
arrangement would reduce the cost of CME while, at 
the same time, increasing the sale of and subscription 
to your journal. 
John Hartley 
Truro, Cornwall, UK 
To Dr Hartley: 
We are pleased that at least one reader has found the 
M C Q  section in the first Continuing Education article 
useful, and we welcome any other comments on the 
format. Subsequent articles in this section will continue 
to include multiple-choice questions. 
The possibility of linking these M C Q  to formal 
schemes of continuing education and accreditation has 
been discussed. The degree of development and the 
details of such systems among the European countries 
vary considerably. We believe that, at the present time, 
we should not link our MCQs to participation in 
particular schemes, but continue to provide answers for 
immediate use in self-assessment. In the future, it is 
hoped that CME and accreditation will be carried out 
on a European basis, possibly with the involvement of 
the European Society of Clinical Microbiology and 
Infectious Diseases. At such a time, Clinical Microbiology 
and Injection will be eager to collaborate on such a 
scheme. 
David C. E. Speller 
Co-Editor 
Risk-factor analysis and diagnostic index for 
Pseudomonas aeruginosa bacteremia 
To the Editors: 
Re:  Gransden et al., Clin Microbiol Infect 1995; l(2): 
119-23 
Dr Gransden and his colleagues identified neutropenia, 
cytotoxic or corticosteroid treatment, male gender, 
acquisition of infection in hospital, detection of 
bacteremia in the intensive care unit, previous or 
current antibiotic treatment and site of infection as risk 
factors for Psendomonas aernginosa bacteremia. O n  the 
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basis of these factors, they established an individual 
diagnostic index to define those groups of bacteremic 
patients who are at low or  high risk of I? aevuginosa 
bactereniia. Those associated factors (such as neutrophil 
defects, intensive care and cytotoxic or antibiotic treat- 
ment) identified by Gransden and coworkers have 
previously been recognized in several studies to render 
hospital patients particularly susceptible to I? aeuuginosa 
infection. In addition, the chances of identifying purely 
‘local’ factors that were not of general value was limited 
by the use of two different sets of patients from two 
different hospitals. The basic results of their study 
therefore appear to be well founded. 
Nevertheless, as was suggested by the authors 
themselves in the last paragraph of their report, the 
study did not provide useful information for the 
clinician, especially the intensivist, who is required 
daily to answer the following questions: Is the patient 
with a septic appearance truly bactereniic, and is this 
possibly bactereniic patient at  high risk of I? aeruginosa 
bacteremia? The design of the study and particularly 
the study population, which was limited to patients 
with bactereniia, do not help to answer these questions. 
Analysis of risk factors based on the comparison of 
patients with I! acvug’inosa bacteremia with those who 
have bactereniia due to other pathogens can only 
evaluate the likelihood with which l? aeruginosa was 
responsible after bacteriological diagnosis of bacteremia. 
Furthermore, the diagnostic index defined only those 
groups of bactereniic patients in whom I? aevuginosa was 
more likely to be causative than other pathogens. 
Is the use of such an index clinically relevant in 
patients known to be bacteremic (before determination 
of the staining and morphological characteristics of 
the bacteria isolated in the blood)? Are the initial 
therapeutic strategies different in the case of a 5.50/0, 
17.6% or 22.3% risk of bactereniia due to I? ueruginosa, 
as in the first validation set? Risk analysis remains the 
niajor epidemiological objective in different clinical 
settings, particularly acquisition of nosoconiial in- 
fection. Similarly, determination of groups of high-risk 
patients is one possible way to use prophylactic nieasures 
effectively. Such a determination, however, must be 
well founded and useful in clinical practice. 
Jean- Yves Fagon 
Paris, France 
Malignant ventricular arrhythmia during treatment 
with terfenadine and itraconazole: 
A pharmacokinetic study 
To the Editors: 
Terfenadine is a widely used non-sedating HI-selective 
antihistamine which has occasionally been associated 
with cardiac arrhythmias such as tovsades de  pointes, 
during overdosage [1] and in combination with other 
agents, such as ketoconazole [2,3] or some macrolide 
antibiotics [4]. The cardiac toxicity is the result of 
the direct quinidine-like action of terfenadine [5]. 
Recently, two reports have documented the occur- 
rence of cardiac arrhythmia during combined terfena- 
dine and itraconazole treatment [6,7]. To follow is a 
report of a case of malignant ventricular arrhythmia 
during treatment with this drug combination and a 
pharniacokinetic study of the two agents. 
An 18-year-old man was referred to our hospital 
in November 1993 with acute monocytic leukemia. 
Physical examination revealed no abnorniality except a 
raised body temperature. Serum electrolyte concen- 
trations were normal. Electrocardiography (ECG) on 
admission showed a corrected QT (QTc) interval of 
340 nis at  a heart rate of 78 beatsmin-’. Transthoracic 
echocardiography was normal. The patient received 
intravenous antineoplastic chemotherapy, including 
idarubicin (13 mg/day for 5 days), cytosine-arabinoside 
(330 nig/day for 7 days) and broad-spectrum antibiotics 
for the persistent fever. All investigations for an infec- 
tive agent were negative. The patient was then given 
prophylactic itraconazole (400 trig once daily; Janssen, 
Boulogne-Billancourt, France) as well as terferiadirie 
(60 nig twice daily; Marion Merrell I h w ,  Levallois- 
Perret, France) because of the pruriginous toxiderniia. 
All of the drugs were administered by a nurse. Ikspite 
broad-spectrum antibacterial therapy, the patient 
remained febrile and intravenous aniphotericin B 
(1 nig/kg/day) was prescribed. O n  the sixth day of 
itraconazole and terfenadine therapy, the patient 
experienced transient generalized seizures arid cardiac 
arrest. The ECG demonstrated ventricular fibrillation. 
The patient’s serum potassium concentration was 
3.4 niniol/L and serum magnesium concentration 
was 0.92 mmol/L. Liver and kidney functions were 
normal. Resuscitation procedures included the use of 
mechanical ventilation, application of four electric 
shocks and administration of niagnesium sulfate. 
Terfenadine and itraconazole were discontinued on the 
same day, after which no arrhythmia or seizure was 
observed. The QTc  interval remained prolonged for 3 
days after cardiac arrest and, after 15 days, the patient 
developed neurological symptoms related to anoxic 
encephalopathy and persistence of blast cells in the 
bone marrow. 
Blood samples were taken 10, 23, 32, 48, 56, 72  
and 96 h after the last dose of terfenadine and kept 
frozen until needed. Itraconazole and hydroxyitra- 
conazole were determined by liquid chromatography 
with fluorescence detection. In brief, a Hypersil 011s 
5 p 250 x 4 nini column was used, with a mobile phase 
